BOO and DU and Their Clinical and Urodynamic Findings in Women With ≥Stage II Cystocele
NCT ID: NCT03613324
Last Updated: 2018-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
455 participants
OBSERVATIONAL
2011-01-01
2018-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence Rates of USI, BO, DO and Their Clinical and Urodynamic Findings in Women With ≥Stage II Cystocele
NCT03613350
Detrusor Underactivity and Bladder Outlet Obstruction in Women With Cystocele
NCT04184128
Evident, Occult and no Demonstrated USI and UDS Findings in Women With ≥Stage II Cystocele
NCT03613311
Prevalence of Detrusor Underactivity and Bladder Outlet Obstruction in Female Without Cystocele
NCT04184752
DU and BOO in Women With and Without Symptoms of VD
NCT04981080
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bladder outlet obstruction (BOO)
Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having BOO when Qmax was \<12 mL/s and PdetQmax was ≥25 cmH2O with sustained detrusor contraction during voiding cystometry.
Pad test
20-minutes pad test and urodynamic study including uroflowmetry, filling cystometry and voiding cystometry.
Detrusor underactivity (DU)
Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having DU when Qmax was \<12 mL/s and PdetQmax was \<10 cmH2O during voiding cystometry.
Pad test
20-minutes pad test and urodynamic study including uroflowmetry, filling cystometry and voiding cystometry.
ND BOO/DU
Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. This group revealed no demonstrated bladder outlet obstruction nor detrusor underactivity.
Pad test
20-minutes pad test and urodynamic study including uroflowmetry, filling cystometry and voiding cystometry.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pad test
20-minutes pad test and urodynamic study including uroflowmetry, filling cystometry and voiding cystometry.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Cystocele \> stage II
3. Complete pad test and urodynamic study
Exclusion Criteria
2. Urinary tract infection
3. Had received pelvic reconstruction surgery
20 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Taiwan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201805025RINB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.